Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors

NCT07688356 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Primary Brain Tumor
Metastatic Brain Tumor

Interventions

DRUG: Belvarafenib

Sponsor

Samsung Medical Center

Collaborators

[object Object]